'Highly efficacious' shingles vaccine excluded from NIP

The vaccine's cost and long-term effectiveness remain in doubt, says the PBAC

A promising new shingles vaccine won't be included on the National Immunisation Program because of doubts surrounding its cost and long-term effectiveness, the Pharmaceutical Benefits Advisory Council says.


The government was considering listing GSK’s recombinant zoster vaccine Shingrix on the National Immunisation Program (NIP) for adults in their 60s.

But despite determining Shingrix to be more effective than the NIP-listed live attenuated vaccine Zostavax, the Pharmaceutical Benefits Advisory Council (PBAC) says